A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Bone Marrow Transplantation for High-risk Solid Tumors
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Allogeneic stem cell therapy; Cyclophosphamide; Fludarabine; Melphalan; Sirolimus
- Indications Solid tumours
- Focus Therapeutic Use
- 13 Apr 2021 Biomarkers information updated
- 12 Mar 2013 New trial record